ASPA rs786204572: Understanding Canavan Disease Carrier Status
The genetic variant rs786204572 is a specific alteration located within the ASPA gene. It is recognized in clinical literature as a carrier mutation associated with Canavan disease, a rare neurodegenerative condition.
What each genotype means
Typical ASPA genotype
This is the most common genotype observed in the general population. Individuals with this genotype do not carry this specific variant associated with Canavan disease.
This is the most frequent genotype found across all global populations.
Canavan disease carrier
You carry one copy of this variant, which is associated with Canavan disease. As this condition is inherited in an autosomal recessive manner, carriers are typically asymptomatic and are not at risk of developing the disorder itself.
This genotype is rare in the general population.
Potential Canavan disease risk
You carry two copies of this variant. Research indicates this genotype is associated with the development of Canavan disease, a rare neurodegenerative disorder. Please consult with a medical geneticist or your healthcare provider to discuss these results and their clinical implications.
This genotype is extremely rare.
What is rs786204572?
The variant rs786204572 is a single nucleotide polymorphism (SNP) situated on chromosome 17. In the context of human genetics, it is often studied alongside the ASPA gene, which provides the blueprint for the enzyme aspartoacylase. This specific variant represents a change in the DNA sequence that can impact the production or function of this enzyme. Because it is located in a gene critical for neurological health, researchers and clinicians monitor such variants to understand their potential impact on biological processes. It is important to note that identifying a variant like rs786204572 is a standard part of genomic research, helping scientists map the landscape of human genetic diversity and identify markers that may contribute to rare inherited conditions.
The Role of the ASPA Gene
The ASPA gene is responsible for producing the enzyme aspartoacylase. This enzyme plays a vital role in the brain by breaking down a compound called N-acetyl-L-aspartic acid (NAA). When the ASPA gene functions correctly, NAA is processed efficiently, which is essential for the maintenance of myelin, the protective sheath that covers nerve fibers. If the ASPA gene contains pathogenic mutations that significantly reduce or eliminate enzyme activity, NAA can accumulate to toxic levels in the brain. This accumulation is the hallmark of Canavan disease, a condition characterized by the progressive degeneration of white matter. Understanding the function of the ASPA gene is crucial for grasping why certain variants are classified as pathogenic or carrier-related, as they directly interfere with this essential metabolic pathway.
Research and Clinical Evidence
Research into rs786204572 has identified it as a marker associated with Canavan disease. Canavan disease is an autosomal recessive disorder, meaning an individual typically needs to inherit two copies of a pathogenic mutation—one from each parent—to manifest the condition. Carriers, who possess only one copy of such a variant, generally do not show symptoms of the disease. The evidence linking specific ASPA variants to this condition is well-documented in clinical databases like ClinVar and through peer-reviewed studies. While the association between ASPA mutations and Canavan disease is strong, the clinical significance of any single variant can vary based on the specific genetic context. Geneticists use this information to provide context for carrier screening programs, which help families understand their reproductive risks.
Population Frequency
The variant rs786204572 is considered rare in the general population. While some specific ASPA mutations have higher carrier frequencies in certain ancestral groups, such as the Ashkenazi Jewish population, the prevalence of any individual variant can differ significantly across global populations. Because this variant is rare, it is not commonly found in the general screening of the broader public. Genetic databases like gnomAD provide data on the frequency of such variants, which helps researchers determine how common a mutation is within different ethnic and geographic groups. This data is essential for interpreting the results of genetic tests, as it provides a baseline for how often a particular variant appears in healthy individuals versus those affected by a specific condition.
Navigating Genetic Information
If you have received information regarding your status for rs786204572, it is important to understand what this means in a clinical context. Being identified as a carrier for a recessive condition does not mean you have the disease, nor does it mean you will develop it. However, this information is valuable for family planning and understanding potential risks for future children. You cannot use this information to diagnose yourself or others, and it should not be used to make medical decisions without professional guidance. If you are concerned about your carrier status or the implications of a genetic report, the most appropriate step is to consult with a certified genetic counselor or a medical professional. They can provide personalized context, explain the inheritance patterns, and discuss the limitations of genetic testing.
How common is this variant?
The variant rs786204572 is rare in the general population, though carrier frequencies for ASPA mutations can be higher in specific ancestral groups.
Frequently asked questions
What is Canavan disease?
Canavan disease is a rare, inherited neurodegenerative disorder caused by mutations in the ASPA gene. It leads to the accumulation of N-acetylaspartic acid in the brain, which damages the myelin sheath and affects brain development.
Does having the A/C genotype mean I have Canavan disease?
No, having the A/C genotype typically identifies you as a carrier. Carriers have one copy of the variant and one normal copy, which is usually sufficient for the body to produce enough functional enzyme to prevent the disease.
Should I be tested for ASPA mutations?
Carrier screening is often recommended for individuals with a family history of Canavan disease or those from populations with a known higher carrier frequency. You should discuss the necessity and implications of such testing with a healthcare provider or genetic counselor.
Is there a cure for Canavan disease?
Currently, there is no cure for Canavan disease, and treatment is primarily supportive, focusing on managing symptoms and improving quality of life. Research into gene therapy and other potential treatments is ongoing.
Sources & further reading
Educational information only, last refreshed 9/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs786204572?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ASPA
Common pathogenic nonsense mutation (p.Tyr231Ter / p.Y231X) in ASPA underlying Canavan disease.
Severe pathogenic ASPA nonsense mutation (p.Tyr231Ter) responsible for Canavan disease in reproductive carrier screening.
Pathogenic ASPA missense variant (p.Glu285Ala) causing aspartoacylase deficiency (Canavan disease), standardly tested in preconception carrier panels.
A nonsense mutation (c.693C>A, p.Tyr231Ter) in ASPA leading to truncated aspartoacylase and defining carrier status for Canavan disease.
A missense mutation (c.854A>C, p.Glu285Ala) in aspartoacylase causing Canavan disease in the homozygous state, representing one of the most common Jewish carrier screening alleles.
Pathogenic missense variant (p.Glu285Ala) causing aspartoacylase catalytic failure and severe leukodystrophy characteristic of Canavan disease.